ProjectRD.06.SPR.118161 – A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of…

Basic data

Acronym:
RD.06.SPR.118161
Title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
Duration:
2/8/2021 to 2/1/2022
Abstract / short description:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with
Moderate-to-Severe Atopic Dermatitis
Keywords:
atopic dermatitis
Atopische Dermatitis

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Other staff

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

La Tour-de-Peilz, Switzerland
Help

will be deleted permanently. This cannot be undone.